
IBKR · Nasdaq
Consensus is Buy, supported by all nine analysts tracked, with a mean price target of $111. The supplied data provide no low or high targets, so the target spread cannot be measured, and they do not identify the most or least bullish analyst. No rating or target revisions are explicitly reported during the past week, leaving revision direction unavailable. The substantive disagreement is between the constructive aggregate view and Zacks' warning that brokerage recommendations can be overly optimistic. Zacks separately frames IBKR's 8.6% monthly decline as a potential opportunity because of product expansion and growth forecasts, but the evidence does not quantify those forecasts or establish a target range.